162 related articles for article (PubMed ID: 38069368)
1. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer.
Geng P; Zhao J; Li Q; Wang X; Qin W; Wang T; Shi X; Liu X; Chen J; Qiu H; Xu G
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069368
[TBL] [Abstract][Full Text] [Related]
2. Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism.
Jiang X; Zhao W; Zhu F; Wu H; Ding X; Bai J; Zhang X; Qian M
Toxicol Appl Pharmacol; 2021 Jan; 410():115336. PubMed ID: 33212065
[TBL] [Abstract][Full Text] [Related]
3. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
4. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
[TBL] [Abstract][Full Text] [Related]
5. Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from Angelica sinensis against cisplatin toxicity in vitro.
Bunel V; Antoine MH; Nortier J; Duez P; Stévigny C
Toxicol In Vitro; 2015 Apr; 29(3):458-67. PubMed ID: 25561245
[TBL] [Abstract][Full Text] [Related]
6. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa.
Ma H; Li L; Dou G; Wang C; Li J; He H; Wu M; Qi H
Oncotarget; 2017 Apr; 8(17):29328-29345. PubMed ID: 28415616
[TBL] [Abstract][Full Text] [Related]
7. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
8. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
[TBL] [Abstract][Full Text] [Related]
9. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
10. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
12. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages.
Qi H; Jiang Z; Wang C; Yang Y; Li L; He H; Yu Z
Oncotarget; 2017 Apr; 8(17):29300-29317. PubMed ID: 28431397
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of METTL14-mediated m
Gong S; Wang S; Shao M
J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
[TBL] [Abstract][Full Text] [Related]
16. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
[TBL] [Abstract][Full Text] [Related]
18. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
19. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
20. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]